Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Vitamin D and Reduction of Breast Cancer Risk

Vitamin D and Reduction of Breast Cancer Risk Vitamin D is important in mammary homeostasis, but the vitamin D signaling pathway is dysregulated in breast cancer epithelial cells. Preclinical and several ecologic and associational studies suggest an inverse relation between vitamin D intake or 25-OH D3 levels and mammary cancer risk, particularly in younger women. However, human correlative and interventional trial results are inconsistent, perhaps due to differences in cohort selection, research methodology, confounding influences, or a small magnitude of effect. Significant risk reduction may require blood 25-OH D3 of >50 ng/mL, a level much higher than that generally observed in Western populations in cohort studies or after low doses of supplements in placebo-controlled intervention trials. Ongoing phase II trials in premenopausal women are designed to achieve levels of 25-OH D3 of ≥50 ng/mL and assess impact on risk biomarkers for breast cancer. These studies will inform design of future cancer incidence trials. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Breast Cancer Reports Springer Journals

Vitamin D and Reduction of Breast Cancer Risk

Fabian, Carol
Current Breast Cancer Reports , Volume 3 (3) – Jul 16, 2011
Download PDF
9 pages

Loading next page...
 
/lp/springer-journals/vitamin-d-and-reduction-of-breast-cancer-risk-wMXFSgOMFw

References (72)

Publisher
Springer Journals
Copyright
Copyright © 2011 by Springer Science+Business Media, LLC
Subject
Medicine & Public Health; Internal Medicine; Oncology; Surgical Oncology
ISSN
1943-4588
eISSN
1943-4596
DOI
10.1007/s12609-011-0052-6
Publisher site
See Article on Publisher Site

Abstract

Vitamin D is important in mammary homeostasis, but the vitamin D signaling pathway is dysregulated in breast cancer epithelial cells. Preclinical and several ecologic and associational studies suggest an inverse relation between vitamin D intake or 25-OH D3 levels and mammary cancer risk, particularly in younger women. However, human correlative and interventional trial results are inconsistent, perhaps due to differences in cohort selection, research methodology, confounding influences, or a small magnitude of effect. Significant risk reduction may require blood 25-OH D3 of >50 ng/mL, a level much higher than that generally observed in Western populations in cohort studies or after low doses of supplements in placebo-controlled intervention trials. Ongoing phase II trials in premenopausal women are designed to achieve levels of 25-OH D3 of ≥50 ng/mL and assess impact on risk biomarkers for breast cancer. These studies will inform design of future cancer incidence trials.

Journal

Current Breast Cancer Reports – Springer Journals

Published: Jul 16, 2011

There are no references for this article.